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Summan' of the thesis
Summary
Vincristine, one of the naturally occurring vinca alkaloids extracted from the
leaves of the periwinkle plant Catharanthus roseus. remains to be an important
anti-neoplastic drug in paediatric oncology since its introduction in the early
nineteen sixties. Vincristine is active against acute leukaemia, Hodgkin's and non-
Hodgkin's lymphoma, soft tissue sarcoma, Wilm's tumour, brain fumour and
neuroblastoma. The dose-limiting side effect consists of a peripheral sensory,
motor, and autonomic neuropathy. Other side effects, such as bone-marrow
suppression, are relatively mild and no serious long-term side effects are known.
Because of its wide applicability and relatively mild bone-marrow suppression,
vincristine is easy to combine with other anti-neoplastic drugs in a combination
chemotherapy regimen. Therefore, it is worthwhile to try to optimize the treatment
with vincristine in children.
Two goals can be distinguished when trying to optimize vincristine treatment:
suppression of side effects and inrprovement of efficacy. The research presented in
this thesis was focussed on improvement of vincristine efficacy. The antileukaemic
effect of vincristine is principally determined by two factors: systemic exposure to
vincristine and in vivo cell sensitivity to vincristine. First we hypothesized that the
antileukaemic effect of vincristine might vary between patients as a consequence of
interindividual variability in vincristine systemic exposure. If antileukaemic effect
and systemic exposure are correlated, we could try to improve response by
pharmacokinetically guided adaptation of the vincristine dose in each patient. The
second part of the thesis was focussed on the mechanism of action of vincristine
since better knowledge of its mechanism of action might help to understand
differences in cell sensitivity to vincristine.
To place vincristine in a broad perspective of cancer chemotherapy in
children, in chapter I we reviewed the current knowledge of pharmacokinetics and
-dynamics of some anti-neoplastic drugs, used in the treatment of childhood
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cancer, and the experience with pharmacokinetically guided, individualized dosing.
Of all reviewed anti-neoplastic drugs, methotrexate appears to be most extensively
studied. Methotrexate pharmacokinetics is correlated with toxicity and response to
therapy, and individualtzed adaptive dosing of methotrexate is correlated with a
better response to therapy, without increasing toxicity, in children with acute
lymphoblastic leukaemia and osteosarcoma. For most of the other reviewed anti-
neoplastic drugs, including vincristine, it is demonstrated that pharmacokinetics i
correlated with toxicity. Of some drugs a relationship of pharmacokinetics with
response to therapy is demonstrated as well. In case of cytarabine, etoposide, and
teniposide, individualized dosing also appears to be feasible. However, there is no
evidence that this strategy improves response to therapy. In children with acute
lymphoblastic leukaemia and/or acute myeloid leukaemia, ct4arabine and
teniposide adaptive dosing did not improve response. The effect of etoposide
adaptive dosing on toxicity and response to therapy has not been studied up till
now. Future research might answer the question whether this strategy improves
etoposide response, and whether pharmacokinetics of carboplatin, ifosfamide,
paclitaxel, and vincristine are correlated with response in children. There is a lack
of knowledge on pharmacokinetic and -dynamic correlations in children for the
anthracyclines, bleomycin, cispiatin, cyclophosphamide, and vinblastine. The
research presented in this thesis, addresses the question whether pharmacokinetics
of vincristine is correlated with response to vincristine monotherapy.
In the review. we also summarized existing knowledge from previous studies
on vincristine pharmacokinetics and -dynamics. Vincristine is usually administered
as an intravenous bolus dose and its disposition is described by a two-
compartment, first-order model. Mean (SD) terminal elimination half-life and
systemic clearance in children varied from 13.7 (6.5) to 18.7 (18.8) hours and 357
(146) to 482 (342) mlimin/m2 respectively, in different reports. In adult lung cancer
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interindividual variability of pharmacokinetic parameters in children appeared to
be large.
Renal elimination of vincristine accounts for approximately l}Vo of systemic
clearance in adults. Vincristine is predominantly excreted by the hepatobiliary
pathway and a considerable amount of the parent drug is subject to hepatic
metabolism before excretion into the bile. In line with the important role of hepatic
clearance in vincristine elimination, increased serum alkaline phosphatase
concentrations were associated with increased systemic exposure and elimination
half-life of vincristine in a group of adult cancer patients, suggesting impaired
hepatobiliary elimination. In several case reports severe vincristine toxicity was
associated with co-administration of CYP3A4 inhibiting drugs during vincristine
treatment and in some studies vincristine pharmacokinetics appeared to be affected
by these drugs.
In each of the previous pharmacokinetic studies of vincristine in children,
vincristine was administered in combination with other cytotoxic drugs or
corticosteroids. Drug interactions may have contributed to the large interindividual
variability that was detected in these studies. In chapter 2, we described the
pharmacokinetics of vincristine as a monotherapy in a group of 70 children newly
diagnosed with acute lymphoblastic leukaemia. Thus, these patients did not receive
corticosteroids or other cytotoxic drugs during the period of the study. Vincristine
plasma concentrations were measured by HPLC analysis, after a single dose of i.5
mg/m2 vincristine i.v. The data were fitted according to a two-compartment, first-
order pharmacokinetic model by maximum a posteriori parameter estimation and
secondary pharmacokinetic parameters were calculated from the model. In this
relatively homogeneous group of children pharmacokinetic parameters were highly
variable: median (25th and 75'h percentiles) total body clearance,228 (128 - 360)
ml/rnin'm2; elimination halflife, 1001 (737 - 1325) min; apparent volume of distri-
bution at steady state,262 (158 - 469)Llm2. Variability of vincristine pharmaco-
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kinetics remains largely unexplained despite examination of the influence of
several demographic and biochemical variables. However, vincristine clearance is
substantially slower than has been reported previously for children receiving
vincristine in combination with steroids as part of combination chemotherapy
(median clearance, 228 mllmin'mt uersus mean clearance, 381 and 482 ml/min'm2,
respectively). Steroids are known as inducers of vincristine-metabolizing CYP3A4
enzymes. The absence of steroids during our sfudy appears to be the most likely
explanation for this difference.
ln chapter 3 we addressed the question whether pharmacokinetics of
vincristine is correlated with response to vincristine monotherapy. In the above
mentioned group of 70 children newly diagnosed with acute lymphoblastic
leukaemia, not only pharmacokinetic parameters were studied but response to
vincristine monotherapy was studied as well. Before and three days after
administration of a bolus dose of 1.5 mg/m: vincristine. the percentage of
lymphoblasts was determined on bone maÍrow and peripheral blood smears. In
addition, the white blood cell count was determined, which allowed evaluation of
three response parameters: a decrease of the percentage of lymphoblasts in bone
maffow and peripheral blood, and a decrease of the absolute number of
lymphoblasts in peripheral blood. The combination of at least one response
parameter and vincristine pharmacokinetics was available in 54 patients. Results of
the study in chapter 3 show that variability of response to vincristine monotherapy,
in bone maÍïow and peripheral blood, could not be attributed to interindividual
variability of vincristine systemic exposure. The lack of pharmacokinetic and -
dynamic correlations, demonstrated in this study, does not support a role for
therapeutic drug monitoring of vincristine in children with acute lymphoblastic
leukaemia.
Our second approach to improve vincristine efficacy was focussed on
vincristine's mechanism of action, since an important step to better efficacy of a
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drug is an improved knowledge of its mechanism of action. The antileukaemic
effect of vincristine is traditionally attributed to inhibition of cell cycle progression
due to interference with microtubule dynamics. However, it was also shown in
vitro thaÍ vincristine induces apoptosis in leukaemic cell lines. Apoptosis is a
process of cell death characterized by nuclear fragmentation with double-stranded
DNA breaks, and cytoplasmic condensation and formation of apoptotic bodies,
which can be removed by phagocy'tosis. The investigational up-front window
study, described in this thesis, provided a unique opportunity to study vincristine-
induced apoptosis in vivo in children with acute lymphoblastic leukaemia.
The results described in chapter 4, demonstrate that vincristine induces
apoptosis ín vivo in peripheral blood mononuclear cells, mainly lymphoblasts, of
children with acute lymphoblastic leukaemia. In five patients, participating in the
investigational up-front window srudy of DCLSG protocol ALL-9, extra peripheral
blood samples were collected on the first day of the study. The sampling was
scheduled before and 3, 8, 12, 16, 20, and 24 h after vincristine administration.
Peripheral blood mononuclear cells were isolated by density gradient
centrifugation of the blood on Ficoll-Paque. The TTINEL (terminal deoxv-
nucleotide íransferase-mediated UTP-digoxigenin nick-end labelling) assay was
performed on 40Á paraformaldehyde-fixed cytospin slides of mononuclear cells to
detect apoptosis. In one patient, a striking increase of apoptotic cells from 27o
(SEM 0.6) before to 40.7oÁ (SEM 2.9) 3 h after vincristine injection was found. In
the other patients the maximum increase ranged from 0.8%o to 4.3oÁ. Wilcoxon
matched pairs analysis of all patients confirmed that vincristine induces apoptosis
in vivo in peripheral blood mononuclear cells in children with acute lymphoblastic
leukaemia.
In chapter 5 we further studied the route of vincristine-induced apoptosis. In
the process of apoptosis caspases play a critical role. Caspases are cysteine
proteases that exist as proenzymes and are activated upon cleavage. In cell-free
171
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extracts activation occurs in a hierarchical order. Evidence is accumulating that the
caspase cascades differ depending on the apoptotic stimulus. In apoptosis induced
by CD95-receptor signalling, caspase-8 is the most proximal caspase, activated by
autoproteolysis after recruitment to the intracellular located adaptor proteins FADD
of the CD95-receptor complex. In apoptosis induced by apoptotic stimuli that
activate the mitochondrial controlled pathway, the most proximal caspase is
caspase-9, which can be activated after cytochrome C and dATP-dependent
formation of a caspase-9lApaf-| complex. It is shown that mitochondrial changes
such as cy'tochrome C release, loss of mitochondrial membrane potential and the
production of reactive oxygen species. can precede caspase-9 activation during
apoptosis. Furthermore, it is known that the pro- and anti-apoptotic members of the
Bax/Bcl-2 protein family regulate mitochondrial cyochrome C release and
apoptosis. Apoptosis induced by several DNA-damaging anti-neoplastic drugs does
not require CD95-receptor signalling but most often follows a CD95-independent,
mitochondrial controlled pathway. It is unclear whether apoptosis induced by
vincristine proceeds by a mitochondrial controlled pathway.
The results presented in chapter 5 demonstrate caspase-9 and -3 activation ir
vivo in bone marrow leukaemic cells of a child with newly diagnosed acute
lymphoblastic leukaemia, after treatment with a single dose of vincristine. We
hypothesized that vincristine induces apoptosis by a mitochondrial controlled
pathway and we further studied its mechanism of action in Jurkat acute
lymphoblastic leukaemia cells. Vincristine-induced activation of caspase-9 and
subsequently caspase-3 was demonstrated by western blot analysis of cell lysates,
prepared after exposing Jurkat cells to vincristine with or without the caspase-9
inhibitor Z-LEHD-FMK. Loss of mitochondrial transmembrane potential was
independent of caspase-9 activation. To confirm the mitochondrial role in
vincristine-induced apoptosis, the effect of blocking the mitochondrial route


























was 5 to 20 ti
We conr










Lne potential and the
-9 activation during
'totic members of the




) and -3 activation in
vly diagnosed acute
s of vincristine. We
chondrial controlled
on in Jurkat acute
rn of caspase-9 and






Summam of the thesis
oxygen species scavenging and Bcl-2 overexpression. We found that generation of
reactive oxygen species was detected early in Jurkat cells during vincristine
exposure. Ascorbic acid, a reactive oxygen s:recies scavenger. inhibited reactive
oxygen species generation as well as caspase-9 and -3 activation and cell death
induced by vincristine. Furthermore, in Bcl-2 overexpressing Jurkat cells
mitochondrial transmembrane potential changes, caspase-9 and -3 activation, and
cell death upon vincristine exposure were decreased, in comparison to parental
Jurkat cells. However, generation of reactive oxygen species was not decreased in
Jurkat cells with Bcl-2 overexpression. We concluded that reactive oxygen species
play a regulatory role in the initial phase of a mitochondrial controlled pathway of
vincristine-induced apoptosis in acute lymphoblastic leukaemia cells.
We realized that the antileukaemic effect of vincristine in vivo might be
impaired by leukaemic cell resistance to apoptosis. despite adequate intracellular
drug concentrations. Therefore, it would be useful to determine intracellular
concentrations of vincristine in leukaemic cells of patients. ln chapter 6 we
described a high-perforÍnance liquid chromatographic (HPLC) method to measure
vincristine concentrations in human mononuclear cells. This method with on-line
column, solid-phase extraction and electrochemical detection, previously
developed for determination of vincristine concentrations in human plasma, was
validated for determination of intracellular vincristine concentrations over a range
of l.l7 to 50.8 pg/L w'ith a lower lirnit of quantitation of l.l7 pg/L. The method
was used successfully to measure intracellular vincristine concentrations in 8/35
bone marrow mononuclear cell samples of children newly diagnosed with acute
lymphoblastic leukaemia, three days after the first injection of 1.5 mg/m2
vincristine. Vincristine concentrations were in the range of 4.0 to 26.4 pg/L which
was 5 to 20 times the bone marow plasrna concentration.
We conclude that vincristine pharmacokinetic parameters are highly variable,
even in a relatively homogeneous group of children newly diagnosed with ALL,
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and that this variability remains largely unexplained. Vincristine clearance is
substantially slower after vincristine monotherapy than has been reported
previously for children receiving vincristine as part of combination chemotherapy,
which is most likely due to the absence of steroids, inducers of vincristine-
metabolizing cytochrome Pa50 3A4 (CYP3A4) enzymes, in our study. Variability of
response to vincristine monotherapy could not be attributed to interindividual
variability of vincristine systemic exposure. Induction of apoptosis appeared to be
an important mechanism of antileukaemic action of vincristine in vivo tn
mononuclear cells of children newly diagnosed with acute lymphoblastic
leukaemia. Reactive oxygen species play a regulatory role in the initial phase of a
mitochondrial controlled pathway of vincristine-induced apoptosis in Jurkat acute
lymphoblastic leukaemia cells.
Results of the research presented in this thesis suggest that activity of
vincristine-metabolizing CYP3A4 enzymes is an impoÍant determinant of
vincristine systemic exposure. Polymorphisms of the genes coding for CYP3A4
enzymes might be responsible for part of the variability of vincristine systemic
exposure. Studies are presently undertaken to determine CYP3A4 polymorphisms
and its relationship with vincristine pharmacokinetics. Other polymorphisms, e.g.
in the genes coding for drug-efflux pumps, might also play a role. The lack of
pharmacokinetic and -dynamic correlations, demonstrated in this thesis, does not
support a role for individualized adaptive dosing of vincristine in children with
acute lymphoblastic leukaemia at this moment. It is necessary to further unravel the
route of vincristine-induced apoptosis in acute lymphoblastic leukaemia cells and
the role of reactive oxygen species in this pathway. Variability between different
cell l ineages in the ability to eliminate reactive oxygen species might be
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